Edition:
India

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

8.32USD
12:00am IST
Change (% chg)

$0.21 (+2.59%)
Prev Close
$8.11
Open
$8.26
Day's High
$8.35
Day's Low
$7.92
Volume
25,692
Avg. Vol
70,731
52-wk High
$27.77
52-wk Low
$7.20

Select another date:

Mon, Jan 8 2018

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 1B Pharmacokinetic Study Evaluating Ra101495 Sc In Patients With Renal Impairment

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 1B PHARMACOKINETIC STUDY EVALUATING RA101495 SC IN PATIENTS WITH RENAL IMPAIRMENT Source text for Eikon: Further company coverage:

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS

BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC

* RA PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF RA101495 SC IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

BRIEF-Ra Pharmaceuticals posts Q3 loss of $0.68 per share

* Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Ra Pharmaceuticals files for mixed shelf offering of up to $250 million

* Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2A6uuro) Further company coverage:

BRIEF-Ra Pharmaceuticals reports Q2 loss per share $0.56

* Ra Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

* RA Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

Select another date: